TGF-β Receptor II Loss Promotes Mammary Carcinoma Progression by Th17-Dependent Mechanisms

Sergey V. Novitskiy, Michael W. Pickup, Agnieszka E. Gorska, Philip Owens, Anna Chytil, Mary Aakre, Huiyun Wu, Yu Shyr, Harold L. Moses

Research output: Contribution to journalArticlepeer-review

85 Citations (Scopus)

Abstract

We report that interleukin (IL)-17 significantly increases the secretion of CXC chemokine ligand 1 and 5 (CXCL1/5) from mammary carcinoma cells, and that stimulated secretion of CXCL1/5 by IL-17 is down-regulated by TGF-β through the type II TGF-β receptor (TβRII). Carcinoma cells with conditional knockout of TβRII (Tgfbr2 KO) have enhanced sensitivity to IL-17a in the stimulation of chemokine secretion. During polyoma middle T (PyMT)-induced tumor progression, levels of Th17-inducing cytokines TGF-β, IL-6, and IL-23 were increased in PyMT/Tgfbr2 KO tumors, which was associated with an increased number of Th17 cells. IL-17 increased the suppressive function of myeloid-derived suppressor cells (MDSC) on T cells through the up-regulation of Arg, IDO, and cyclooxygenase-2. Treatment of PyMT/Tgfbr2 KO mice with anti-IL-17 Ab decreased carcinoma growth and metastatic burden. Analysis of human breast cancer transcriptome databases demonstrated a strong association between IL-17 gene expression and poor outcome in lymph node-positive, estrogen receptor-negative, or luminal B subtypes, suggesting potential therapeutic approaches. Significance: TGF-β signaling is a major tumor suppressor pathway and is therefore difficult to target therapeutically. Understanding the downstream effects of abrogation of TGF-β signaling in tumor cells may identify processes that can be targeted therapeutically. We present data indicating that targeting IL-17 signaling, a pathway that is greatly enhanced by loss of TGF-β signaling, could provide a therapeutic benefit. Analysis of human databases indicated a specific group of patients in whom treatment could be more efficient.

Original languageEnglish
Pages (from-to)430-441
Number of pages12
JournalCancer Discovery
Volume1
Issue number5
DOIs
Publication statusPublished - 2011 Oct

All Science Journal Classification (ASJC) codes

  • Oncology

Fingerprint Dive into the research topics of 'TGF-β Receptor II Loss Promotes Mammary Carcinoma Progression by Th17-Dependent Mechanisms'. Together they form a unique fingerprint.

Cite this